Obesity treatment CagriSema misses goal of 25% reduction in body weight
Market will never be winner takes all given that different patients will have different requirements
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Maker of blockbuster Wegovy and Ozempic treatments reports 21% rise in third-quarter sales
And valuing the weight-loss drug manufacturers
A big market narrative with an eerie absence of sceptics
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
The fashion world is embracing weight-loss drugs — discreetly
Senator Bernie Sanders accuses Ozempic and Wegovy maker of ‘ripping off’ Americans
Danish pharma company also unveils early data for closely watched oral pill to tackle weight loss
US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Shares in Danish drugmaker fall after second-quarter sales and profits fall short of forecasts
Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Swiss drugmaker unveils promising data for obesity drug
Long waiting list for drug because of shortage of specialist services could hit patients unable to pay privately
UK pharma body criticises maker of Ozempic and Wegovy over failure to report £7.8mn in transfers of value
Danish maker of Wegovy has little competition in the country and massive demand that it can take advantage of
Move opens market with growing rates of obesity to Danish group’s blockbuster drug
Danish pharma group plans 1.4mn sq ft manufacturing plant in North Carolina to help meet surging demand
Both OZEM and THNR offer very concentrated bets on a fast-moving market
The sector’s holy grail of an effective, easily manufactured weight loss pill does not look imminent
Study opens up potential to tackle a condition with few available treatment options
